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Abstract 
The aim of present study was to develop colon targeted system for 
metronidazole using guar gum and xanthan gum. Matrix 
formulations containing various proportions of guar gum and 
xanthan gum were prepared by wet granulation technique using 10% 
starch paste. Later on, multilayer tablets were prepared by using 50 
mg and 100 mg of guar gum as release controlling layer on either 
side of (M5) guar gum matrix tablets of metronidazole. All the 
formulations were evaluated for in-process quality control tests. The 
in-vitro drug release study was undertaken at 37±0.5°C in 0.1N HCl 
for 2 h; followed by pH 7.4 phosphate buffer (3h) finally in, 
simulated colonic fluid pH 6.8 phosphate buffer containing 4%w/v 
rat ceacal content for 15 h. Results indicated that guar gum was 
alone failed to control drug release. M5 (GG: XG, 0:100) 
formulation seems to quiet promising for colonic drug delivery and 
only 12.3% drug is released in first 5h wherease, other matrix tablets 
released 12-33% of metronidazole in physiological environment of 
stomach and small intestine. When studies were continued in colonic 
fluids, matrix tablets released almost 100% drug. whereas, 
metronidazole multilayer formulations did not release drug in 
stomach and small intestine, but delivered drug to the colon resulting 
in slow absorption of the drug and making drug available for local 
action in the colon. 
Keywords: colon-specific tablet, Guar gum, Xanthan gum. 
 
Introduction 
Amoebiasis is an infection of the large intestine 
caused by Entamoeba histolytica, a single celled 
protozoan parasite. The current estimate shows 
that Entamoeba histolytica causes the 34-50 
million symptomatic infections each year and 
leads to the death of 40-100,000 people which 
make amoebiasis second only to malaria as a 
cause of death resulting from protozoan parasite. 
The trophozoites of Entamoeba histolytica can 
invade the colonic epithelium, causing amoebic 
colitis [1]. 
Metronidazole and Ornidazole are the preferred 
drugs used in treatment of the amoebiasis, 
giradiasis, trichomonasis and anaerobic 
infections. These drugs are to be delivered to the 
colon for their effective action against 
trophozoites of E. histolytica and Giradia lamblia 
wherein the respective trophozoites reside in 
lumen of the caecum and large intestine and 
adhere to colonic mucus and epithelial layers. But 
pharmacokinetics profile of metronidazole 
indicates that drug is completely absorbed in 
approximately 1 h after a single dose of 500 mg. 
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The administration of this drug in conventional 
tablet dosage form provides a minimal amount of 
metronidazole for local action in the colon, still 
resulting in the relief of amoebiasis, but with 
unwanted systemic side effects [2] 
 
Various approaches are employed for targeting 
orally administered drugs to the colon include 
coating with pH-dependent polymers, design of 
the timed release dosage forms and the utilization 
of carriers that are degraded exclusively by 
colonic bacteria [3]. The pH-dependent systems 
are designed to release the drug to the above a 
particular pH of gastrointestinal tract (GIT), was 
very well established. The timed release systems 
release their load after a pre-determined time 
period of administration. The time dependent 
formulation are designed to resist the release of 
the drug in the stomach with an additional non-
disintegrating or lag phase included in the 
formulation and the release of the  drug takes 
place in the colon. An example of such system is 
Pulsincap® [4]. Another limitation of time 
dependent release systems are the variation in the 
gastric emptying time and small intestine transit 
time. But, due to the use of enteric coating over 
most of these systems, the large variation in 
gastric emptying is overcome by most of these 
systems [5]. However, there is still likely to be a 
considerable variability in the in-vivo 
performance of the timed-release systems by 
virtue of the variation in small intestinal transit 
time [6-7]. 
 
A variety of metabolic reactions like hydrolysis, 
reduction, decarboxylation, dealkylation etc. are 
carried out by the anaerobic bacteria residing in 
the colon. Colon specific drug delivery system is 
developed on the basis of these metabolic 
reactions includes prodrugs which are cleaved by 
colonic bacterial enzymes thereby releasing the 
actual drug in the colon [8]. The best alternative 
approach for colon specific drug delivery is the 
use of the carriers that are degraded exclusively 
by colonic bacteria. The micro-flora of the colon 
is in the range of 1011-1012 CFU/ml consisting 
mainly of anaerobic bacteria e.g. Bacteroides, 
Bifidobacteria, Eubacteria, Clostridia, 
Enterococci, Enterobacteria and Ruminococcus 
etc. Because of the presence of the biodegradable 
enzymes only in the colon, the use of the 
biodegradable polymers for colon specific drug 
delivery seems to be more site-specific approach 
as compared to the other approaches. These 
polymers shield the drug from the environments 
of stomach and small intestine and are able to 
deliver the drug to the colon. On reaching the 
colon, they undergo degradation by enzyme or 
breakdown of the polymer back bone leading to a 
subsequent reduction in their molecular weight 
and their by loss of mechanical strength [9]. 
 
The present investigation is aimed at using the 
inexpensive naturally occurring and abundantly 
available polysaccharides for colon targeted drug 
delivery. An attempts has been made to formulate 
a dosage form that  - 
1. retards drug release in the tracts of upper 
GIT 
2. consist of biodegradable polysaccharides 
as main constituents 
3. is degradable by a wider range of 
microbial species 
4. shows a rapid drug release in the tract of 
colon due to presence of a high 
concentration of a degradable 
polysaccharides in the tablet, and 
additionally 
5. could be formulated using usual tablet 
techniques [10]. 
 
Working on this rationale, matrices were 
proposed for the above purpose. A drug release 
retarding ingredient belonging to 
polysaccharides, i.e., guar gum and xanthan gum 
were selected for the study. 
 
Guar gum alone has earlier been used in colon 
specific drug delivery system as matrix forming 
material and as a compression coat. Xanthan gum 
is known to have a greater drug release-retarding 
property and synergistically enhanced gel 
properties in presence of glactomannan gums 
such as guars [11]. So, a combination of these 
gums was proposed for achieving these 
objectives. A mixture of these gums was 
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evaluated for its drug release- retarding properties 
under simulated gastrointestinal condition [6, 8, 
12-13] . Guar gum (GG) is natural non-ionic 
polysaccharides derived from seeds of the 
Cyamopsis tetragonolobus (family leguminaciae). 
It consists of linear chains of (1→4)-β-D-
mannopyranosyl units with α-D-galactopyranosyl 
units attached by (1→6) linkage Cross linked 
guar-gum has been used as a drug carrier in 
matrix tablets. It was concluded that guar-gum is 
suitable for preparation of colon specific 
formulations and is suitable as a carrier for drug 
that are not soluble in water [13].  
 
Xanthan gum is a high molecular weight 
polysaccharides gum produced by pure culture 
anaerobic fermentation with gram negative 
bacterium, Xanthomonas compestris. It contains 
D-glucose and D-mannose as a dominant hexose 
unit, along with D-glucuronic acid. It is used in 
oral and topical pharmaceutical formulations as a 
suspending, stabilizing, thickening and 
emulsifying agents [14]. 
 
The present paper describes the development and 
in-vitro evaluation of colon targeted drug 
delivery systems of metronidazole using guar 
gum and xanthan gum as a matrixing agent. 
Matrix tablets and multilayer tablets were 
prepared by using different ratio of guar gum and 
xanthan gum. In-vitro drug release studies were 
carried out on metronidazole matrix and 
multilayer tablets in simulated gastrointestinal 
(GI) fluids in the presence and absence of rat 
ceacal contents. 
 
Method 
Materials 
Metronidazole IP was obtained from M/s J. B 
Chemical & Pharmaceutical Ltd, Mumbai. 
Microcrystalline Cellulose (AvicelTM PH-102), 
Starch Paste was procured from CDH Company, 
New Delhi. Guar gum and Xanthan gum were 
procured from S D Fine Chemical Ltd, Mumbai. 
Magnesium stearate and Talc was also 
incorporated in tablets as glidant and lubricant 
was of S D Fine Chemical Ltd, Mumbai. Other 
excipients used to prepare tablets were of 
standard pharmaceutical grade and all chemical 
reagents used were of analytical grade. 
 
Preparation of Metronidazole matrix tablets: 
Matrix tablets of metronidazole were prepared by 
wet granulation technique using 10% starch paste 
as binder. Microcrystalline cellulose used as 
diluent and mixture of talc-magnesium stearate 
(2:1) were used as a lubricant. Guar gum and 
xanthan gum were included in the formulation in 
various proportions. The composition of different 
formulations used in the study containing 100 mg 
of metronidazole in each case is shown in table 1. 
 
Table 1 Composition of Metronidazole matrix tablets 
containing various ratios of guar gum and Xanthan 
gum (total weight = 300 mg). 
 Quantity (mg) present per 
matrix tablet 
Ingredients M-1 M-2 M-3 M-4 M-5 
Metronidazole 100 100 100 100 100 
Guar Gum 100 65 55 35 0 
Xanthan Gum 0 35 45 65 100 
Microcrystalline 
cellulose 
61 61 61 61 61 
Starch 30 30 30 30 30 
Talc 6 6 6 6 6 
Magnesium Sterate 3 3 3 3 3 
Total (in mg) 300 300 300 300 300 
 
In all the formulations, guar gum and xanthan 
gum was sieved (<250µm) and mixed with 
metronidazole (<150µm) and microcrystalline 
cellulose (<250µm). The powder were blended 
and granulated with 10% starch paste. The wet 
mass was passed through a mesh (1680µm) and 
the granules were dried at 50ºC for 2h in hot air 
oven. The dried granules passed through a mesh 
(1190µm) and these granules were lubricated 
with a mixture of talc-magnesium stearate (2:1). 
The lubricated granules were compressed at a 
compression force of 4500-5500 kg using 9.0 mm 
size round, flat and plain punches on a single 
station tabletting machine (M/s Cadmuch 
Machinery, India). The matrix tablets were tested 
for their hardness, drug content and drug release 
characteristics with a suitable number of tablets 
for each test [15]. 
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Preparation of Multilayer Tablets: 
Multilayer tablets of Metronidazole were 
prepared by using 50 mg and 100 mg of guar 
gum as release controlling layer on either side of 
(M5) guar gum matrix tablet formulation of 
metronidazole. Tablets of matrix formulation 
(M5) prepared as described above containing 
GG: XG, 0:100 mg were compressed with either 
side 50 mg or 100 mg of guar gum granules as 
release controlling layer on both side. The 
composition of multilayer tablet G1 and G2 is 
given in table 2 and compressed with a maximum 
force of compressing (4500-5500 kg) using 9.0 
mm size round, flat and plain punches on a single 
station tabletting machine (M/s Cadmuch 
Machinery, India) to obtain multilayer tablets 
[15]. 
 
Table 2 Composition of Metronidazole Multilayer 
Tablets. 
Ingredients Quantity (mg) present 
each multilayer tablet 
 G1 G2 
Guar gum for bottom 
layer 
50 100 
GG and XG Matrix 
tablet (M-5) 
300 300 
Guar gum for top layer 50 100 
Total (in mg) 400 500 
 
Determination of drug content in tablet 
formulations: 
The metronidazole matrix tablets and multilayer 
tablets were tested for their drug content. Ten 
tablets were finely powdered; 100 mg of the 
powder were accurately weighted and transferred 
to a 100 ml volumetric flask containing 50 ml of 
methanol and allowed to stand for 6 h with 
intermittent sonication to ensure complete 
solubility of drug. The solution were made up to 
volume and filtered. After filteration, diluted 
suitably and estimated for metronidazole content 
at 254 nm by using UV-VIS spectrophotometer 
and methanol as a blank [16]. 
 
Physical characteristics of fabricated tablets: 
The weight variation test was conducted as per 
specifications. The crushing strength (Kg/cm2) of 
prepared tablets of Metronidazole was 
determined by using Monsanto tablet hardness 
tester. Friability test of tablets was determined by 
Roche Friabilator at 25 rpm for 4 minutes with 6 
tablets dropping from height of 6 inches with 
each revolution [15-16]. 
 
In-Vitro Drug Release Studies: 
(A) Preparation of simulated colonic fluids: 
Male albino rats weighing 105-115 gm and 
maintained on a normal diet (Bengal gram 
purchased in local market and soaked in water, 
25gm/rat) were used for the study. It was 
reported earlier that rat ceacal content medium at 
4% w/v level obtained after 7 days of enzymatic 
induction with 1 ml of 2% w/w guar gum 
dispersion provide the best conditions for 
assessing the susceptibility of guar gum to 
colonic bacterial degradation. Hence the rats 
were treated with guar gum dispersion for 
inducing the enzymes specifically acting on guar 
gum. The procedure involved oral treatment of 
rats with 1 ml of 2% w/v guar gum dispersion for 
7 days. Thirty minutes before the commencement 
of drug release studies, six rats were euthanized, 
using carbon dioxide asphyxiation. The abdomen 
were opened, the caecai were traced, ligated at 
the both ends with thread, dissected and 
immediately transferred into pH 6.8 phosphate 
buffer saline (previously bubbled with carbon 
dioxide). The ceacal bag were opened, their 
contents were individually weighed, pooled and 
then suspended in the phosphate buffer saline to 
give 4% w/v dilution. As the caecum is naturally 
anaerobic, all the operations were carried out 
under carbon dioxide. The care of the rats was in 
accordance with institutional guidelines [13, 17-
18]. 
In-Vitro Drug Release studies: 
The ability of matrix and multilayer tablets of 
metronidazole to remain intact in physiological 
environment of stomach and small intestine was 
assessed by mimicking mouth to colon transit. 
Drug release studies were carried out using USP-
23 dissolution rate test apparatus [19] (Apparatus 
1, 100 rpm, 37±0.5°C) in 900ml 0.1N HCl for 2h  
(average gastric emptying time is about 2 h). 
Then the dissolution medium was replaced with 
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pH 7.4 phosphate buffer saline (900 ml) and 
dissolution was continued for 3h (average small 
intestinal time is about 3 h). The ability of matrix 
and multilayer tablets of metronidazole to release 
in the physiological environment of colon was 
assessed by continuing the drug release studies in 
presence of rat ceacal content medium. Drug 
release studies were also conducted on 
compression coated matrix and multilayer tablets 
after completing in-vitro dissolution study in 
0.1N HCl  (2h) and pH 7.4 phosphate buffer (3h) 
without rat ceacal content in pH6.8 phosphate 
buffer saline (control study) 
 
The drug release studies were carried out using 
USP-23 dissolution rate test apparatus (Apparatus 
1, 100 rpm, 37±0.5°C) with slight modifications. 
A beaker (capacity 150 ml) containing 100 ml of 
rat ceacal content medium was immersed in the 
water bath of the 1000 ml vessel, which in turn, 
was in the water bath of the apparatus. The 
swollen formulations after completing the 
dissolution study in 0.1N HCl (2h) and pH 7.4 
phosphate buffer saline (PBS) (3h) were placed 
in the baskets of the apparatus and immersed in 
rat ceacal content medium. As the caecum is 
naturally anaerobic, the experiment was carried 
out with continuous carbon dioxide supply into 
the beakers. At different time intervals, 5.0 ml of 
sample was withdrawn and replaced with 5.0 ml 
of fresh phosphate buffer saline bubbled with 
carbon dioxide and the experiment was continued 
for another 15 h as the usual colonic transit time 
is 20-30 h. This 5.0 ml sample is further diluted 
with respective medium, filtered and analyzed for 
metronidazole by UV-VIS Spectrophotometer at 
278 nm, 300 nm and 320nm for 0.1N HCl, pH 
7.4 PBS and pH 6.4 PBS respectively. 
Results and Discussion 
The present study was aimed at developing colon 
targeted formulations of metronidazole using 
guar gum as matrixing agent. It was reported 
earlier that guar gum could be used as a carrier 
for colon specific drug delivery in the form of 
either a matrix tablet or as a multilayer 
compression over the core tablet. Guar gum 
matrix tablets released about 21% of drug 
(Indomethcin) in the physiological environment 
of stomach and small intestine, but released the 
majority of its drug content in the physiological 
environment of colon [13]. However, the release 
of such a small percentage of drugs from the 
surface of matrix tablets in the physiological 
environment of stomach and small intestine is a 
serious consideration for drugs showing the 
deleterious effects on stomach and small intestine 
(e.g. anticancer drugs in treatment of colon 
cancer). In such a situation, it was suggested to 
apply a layer of guar gum over these matrix 
tablets [17]. Hence the attempts were made to 
minimize drug loss under conditions mimicking 
mouth to colonic transit and to ensure maximum 
drug release in the colon by applying guar gum 
and xanthan gum as a matrixing agents in 
different proportions. 
 
Matrix tablet of Metronidazole  
Since guar gum and xanthan gum is found to 
have poor flow properties and is to be 
incorporated in the matrix tablets in larger 
proportions, metronidazole tablets were prepared 
by wet granulation technique using starch paste 
as a binder. The matrix tablets were prepared by 
applying maximum force of compression and 
evaluated for various quality control parameters 
as shown in table 3. All formulations were 
complying with IP specifications [16]. 
 
Table 3 Physiochemical Characteristics of metronidazole colon specific matrix tablets. 
# Matrix formulation 
code 
Average weight 
variation ±sd 
Hardness 
(Kg/cm2) 
Friability % drug content uniformity 
(w/w) ±sd 
1 M-1 301 mg±2.5 5.5±0.144 0.0306 99.1±0.0521 
2 M-2 305 mg±3.5 5.7±0.115 0.052 98.6±0.0341 
3 M-3 298 mg ±3.5 5.8±0.158 0.043 99.7±0.0567 
4 M-4 298 mg±4.5 6.1±0.166 0.052 101.6±0.0768 
5 M-5 302 mg±2.2 6.3± 0.156 0.048 101.4±0.0435 
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The matrix tablets were subjected to in-vitro drug 
release studies in 0.1N HCl (2h), pH 7.4 
phosphate buffer saline (3h) and simulated 
colonic fluids (rat ceacal content medium at 4% 
w/v level, 15h), metronidazole tablets remained 
intact and swollen at the end of 5h of dissolution 
study in the physiological environment of 
stomach and small intestine due to presence of 
water insoluble diluents such as microcrystalline 
cellulose. The cumulative percentage drug release 
versus time profile (figure-1, table-4) of prepared 
matrices showed that the presence of xanthan 
gum in the tablet retards the drug i.e., as the 
amount of xanthan gum in tablet get increased of 
drug, release from tablets is decreased. In M-5 
(GG:XG, 0:100) tablets drug release is highly 
retarded and only 12.3±3.9% drug is released in 
first 5 h of dissolution (the usual upper GIT 
transit time) as against 33.9±3.5% drug release 
observed in case of M-1 (GG:XG, 100:0). In both 
cases, studies were further performed for 15h in 
pH 6.8 PBS without the rat ceacal content 
medium (control). Considering that the usual 
colonic transit time varies between 20-25 h. The 
M-5 released about 79.4±4.0% of drug and M-1 
released about 89.8±4.0%. Studies were further 
performed in pH 6.8 PBS with the rat ceacal 
content medium (test), showed that M-1 is 
degraded into 2-3 pieces, released 100.2±4.1% of 
its drug with in 15 h while M-5 maintain its 
integrity and released drug 98.76±3.7% over a 
period of time. In order to increase degradable 
portion (making the formulation highly sensitive 
to arrival into the colon) of the tablet and thereby 
reduce the portion of non-degradable 
polysaccharides i.e., XG in the formulation, 
various combinations of GG and XG were tried 
for formulation of optimum dosage form, which 
would show the minimal drug release in the 
upper GIT and still consist of high percentage of 
microbially degradable polysaccharides. So, M-2, 
M-3 and M-4 were formulated. Drug release 
studies showed that M-2 (GG:XG, 65:35) 
released 22.8±2.1% of drug during first 5 h as 
compared to M-3 (GG:XG, 55:45) which 
released only 18.8±1.7% of drug.  
 
From the above results it can be inferred that guar 
gum alone failed to control drug release in the 
physiological environment of stomach and small 
intestine and the presence of xanthan gum in 
tablets retards drug release to a much higher as 
compared to guar gum. The M-5 (GG:XG, 0:100) 
formulation seems quiet promising for colonic 
drug delivery. Hence it was planned to control 
the release of metronidazole by applying different 
amount of guar gum as a release controlling layer 
over the metronidazole matrix formulations (M-
5) (GG:XG, 0:100). 
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Figure-1 cumulative percentage release from matrix 
tablets without rat ceacal content medium. 
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cumulative percentage drug release in presence of rat cecal content
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Figure-2: cumulative percentage release from matrix tablets with rat ceacal content medium. 
 
Table 4 Percentage of Metronidazole released from matrix formulation in 0.1 N HCl  (2h); pH 7.4 Phosphate buffer (3h) 
and pH 6.8 PBS (15 h) without rat ceacal content medium (control) and pH 6.8 PBS(15h) with 4%w/v rat ceacal content 
medium (test). 
# Matrix 
formulation code 
Ratios of 
Gum 
Percentage of Metronidazole released 
   After 2h in 0.1 
N HCl  
After 5 h in pH 
7.4 PBS 
After 20 h in pH 6.8 
PBS (from initial time)  
  GG: XG   Control Test 
1 M-1 100:0 12.2±2.5 33.9±3.5 89.8±4.0 100.2±4.1 
2 M-2 65:35 10.6±1.2 22.8±2.1 86.8±1.3 99.87±4.2 
3 M-3 55:45 8.3±3.1 18.8±1.7 84.6±4.0 98.96±3.3 
4 M-4 35:65 6.1±1.9 14.5±2.8 81.8±3.7 99.56±3.9 
5 M-5 0:100 5.8±2.8 12.3±3.9 79.4±4.0 98.76±3.7 
 
Table 5 Physiochemical Characteristics of Metronidazole multilayer tablets. 
# Formulation Code Average weight  
variation ±sd 
Hardness  
(kg/cm2) 
Friability % drug content 
uniformity (w/w±sd) 
1 G1 398mg±2.3 6.8±0.114 0.0049 99.7±0.0341 % 
2 G2 501mg±3.3 6.7±0.163 0.0052 99.1±0.0568 % 
 
Multilayer tablets of Metronidazole 
Multilayer tablets of metronidazole were 
prepared to control drug release in physiological 
environment of stomach and small intestine i.e., 
up to 5 h of dissolution study. Multilayer tablet 
were prepared by compressing a layer of granules 
containing either 50 mg or 100 mg of guar gum 
on either side of metronidazole of matrix tablet 
(M-5) (GG:XG, 0:100). The hardness of 
Multilayer tablet of metronidazole was found to 
be 6.5-7.0 kg/cm2 and metronidazole present in 
multilayer tablets were found to be in range of 
99.7-101% indicating uniformity of drug content 
as shown in table-5. 
 
Metronidazole multilayer tablets containing 50 
mg (G1) or 100 mg (G2) of guar gum as a release 
controlling layer retained their physical integrity 
up to 20 h of the dissolution study conducted 
without rat ceacal content medium (control), in 
the dissolution medium. In this first 5h of 
dissolution study, multilayer tablet of  
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Figure-3 Cumulative percentage release of multilayer tablets with and without rat ceacal content medium 
 
Table 6 Percentage of Metronidazole released from multilayer formulation in 0.1 N HCl  (2h); pH 7.4 
Phosphate buffer (3h) and pH 6.8 PBS (15 h) without rat cecal content medium (control) and pH 6.8 PBS 
(15h) with 4%w/v rat cecal content medium (test) 
# Matrix formulation 
code 
Cumulative Percentage of Metronidazole released 
  After 2h in 0.1 N HCl  After 5 h in pH 7.4 PBS After 20 h in pH 6.8 PBS 
    Control Test 
1 G1 5.1±1.9 11.0±2.9 74.2±3.7 78.8±3.9 
2 G2 3.9±2.1 9.0±1.4 57.6±4.6 63.5±3.7 
 
 
Metronidazole (G1) released about 11±2.9% 
of Metronidazole whereas, (G2) formulations 
released only 9.0±1.4% of drug indicating 
that G2 formulations could effectively control 
the drug release in the physiological 
environment of stomach and small intestine. 
The percentage of metronidazole released 
from the multilayer tablet of metronidazole 
with and without rat ceacal content medium is 
shown in figure-3. 
 
At the end of 20 h, the percent of 
metronidazole released from G1 in rat ceacal 
content medium, was found to be 78.8±3.9% 
whereas, in control study too, the 
formulations released 74.2±3.9%. However, 
G2 formulation released 63.5±3.7% of 
metronidazole in rat ceacal content medium, 
whereas in control study 57.6±4.6% of drug 
at the end of 20 h was observed. Thus, guar 
gum in the form of the multilayer over the 
metronidazole matrix tablet is capable of 
protecting the drug form being released in 
physiological environment of stomach and 
small intestine. 
 
Conclusion 
The present investigation was carried out to 
develop colon targeted drug delivery system 
for metronidazole using guar gum and 
xanthan gum as carrier for an effective of safe 
therapy of amoebiasis. Matrix tablet of 
metronidazole containing various proportions 
of guar gum and xanthan gum were prepared 
and subjected to in-vitro drug release studies. 
The prepared matrices (GG:XG, 0:100, 
65:35, 55:45) M-1, M-2, M-3 form enzyme 
controlled drug delivery system. M-1 
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formulation is not suitable for colon targeting 
as they degraded into 2-3 pieces at the end of 
dissolution study. M-5 is most promising for 
colonic drug delivery. However in-vitro 
dissolution studies of multilayer tablet of 
metronidazole, G1 and G2 formulations 
showed that G2 formulation is most likely to 
provide targeted drug delivery of 
metronidazole to the colon. 
 
However, in certain diseased conditions of 
the GIT, with a disturbed micro-flora, these 
can provide a drug delivery to the colon since 
these additionally from time controlled 
release system and shall provide a sustained 
drug delivery to the colon. Under the normal 
GIT conditions, with a normal microflora 
they are designed to release the majority of 
drug in the tracts of the ascending colon e.g., 
in local pathologies.  
 
The presence of xanthan gum in tablets not 
only retards initial drug release in upper GIT, 
but also increases susceptibility of the 
matrices to microflora, as higher swelling 
increase surface area available for action of 
enzymes. So, the matrices prepared using the 
usual tabletting techniques were highly site-
specific and could prove ideal for delivery of 
such insoluble molecules to the colon. 
However, the further studies are planned to 
assess the utility of these colon targeted drug 
delivery system of metronidazole in patients 
suffering from amoebiasis.  
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